US biosimilars market is heating up this summer

Right now, the biosimilars market is at a major inflection point, with momentum building in the US Congress for new drug pricing legislation while new biosimilars of America’s bestselling biologic medicine have come to market.

While the summer heats up and folks head out on their vacations, the Biosimilars Council, a division of the Association for Accessible Medicines (AAM), says it remains hard at work advocating for increased patient access to biosimilars and the savings they provide.

The Biosimilars Council released a  new report tracking the uptake of biosimilar insulin products. Based on data from IQVIA, the report found that while demand for unbranded biosimilar insulin products has risen dramatically, patient access has been slowed by payer controls and formulary structure – particularly within Medicare. This report demonstrates the to reduce barriers to biosimilars, so that patients benefit from lower-cost treatments.